QUÉBEC CITY, Aug. 23, 2011
/PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ)
(the "Company") today announced that its Senior Director
Medicinal Chemistry, Matthias Gerlach Ph.D., will present a poster
on novel orally active anticancer Erk inhibitors, at the upcoming
242nd American Chemical Society's National Meeting to be
held August 28 through September 1,
2011 at the Colorado
Convention Center in Denver,
Colorado.
The poster #17068 titled, "Novel
Pyrido[2,3-b]pyrazines as orally active ERK inhibitors", M.
Gerlach, I. Seipelt, G. Mueller, T. Schuster, L. Blumenstein, B.
Aicher, E. Guenther and M. Teifel, will be presented during the two
following sessions:
Date and time:
Poster Session ID:
Venue: |
Monday, August 29, 2011, 8 p.m. - 10 p.m. (Mountain Time)
Sci-Mix (Division of Medicinal Chemistry)
Hall D, Colorado Convention Center |
| |
Date and time:
Poster Session ID:
Venue: |
Wednesday, August 31, 2011, 7 p.m. - 11 p.m. (Mountain
Time)
General Poster session (Division of Medicinal Chemistry)
Four Seasons Ballroom, Colorado Convention Center |
About Erk 1/2 Inhibitor Compounds
Extracellular signal-regulated kinases ("Erks") act in the
Ras-Raf-Mek-Erk signaling cascade and regulate various cellular
processes such as cell growth, proliferation and survival in
response to a variety of extracellular or intrinsically
mutated upstream signals. Aeterna Zentaris has identified small
molecular compounds that selectively inhibit Erk1/2, among them,
AEZS-131, which has shown to significantly inhibit tumor growth in
in vivo studies. Early development of the Erk inhibitor
AEZS-131 is an integral part of Aeterna Zentaris' kinase research
program comprising the investigation of different compounds for
single Erk inhibition, single PI3K inhibition and dual Erk/PI3K
kinase inhibition.
About Aeterna Zentaris Inc.
Aeterna Zentaris is a late-stage oncology drug development
company currently investigating potential treatments for various
cancers including colorectal, multiple myeloma, endometrial,
ovarian, prostate and bladder cancer. The Company's innovative
approach of "personalized medicine" means tailoring treatments to a
patient's specific condition and to unmet medical needs. Aeterna
Zentaris' deep pipeline is drawn from its proprietary discovery
unit providing the Company with constant and long-term access to
state-of-the-art therapeutic options. For more information please
visit www.aezsinc.com.
SOURCE AETERNA ZENTARIS INC.